Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D/A 0001214659-24-017295 0001232621 XXXXXXXX LIVE 2 Common Stock, par value $0.001 per share 05/11/2026 false 0001645666 49372L209 Kezar Life Sciences, Inc. 4000 Shoreline Court Suite 300 South San Francisco CA 94080 Kevin Tang 858-200-3830 4747 Executive Drive Suite 210 San Diego CA 92121 0001232621 N TANG CAPITAL MANAGEMENT, LLC WC N DE 0.00 0.00 0.00 0.00 0.00 N 0 OO 0001178579 N KEVIN TANG WC N X1 0.00 0.00 0.00 0.00 0.00 N 0 IN 0001191935 N TANG CAPITAL PARTNERS, LP WC N DE 0.00 0.00 0.00 0.00 0.00 N 0 PN 0002064011 N TANG CAPITAL PARTNERS INTERNATIONAL, LP WC N DE 0.00 0.00 0.00 0.00 0.00 N 0 PN 0002036763 N TANG CAPITAL PARTNERS III, INC WC N NV 0.00 0.00 0.00 0.00 0.00 N 0 CO 0002036770 N TANG CAPITAL PARTNERS IV, INC WC N NV 0.00 0.00 0.00 0.00 0.00 N 0 CO 0001970065 N CONCENTRA BIOSCIENCES, LLC WC N DE 0.00 0.00 0.00 0.00 0.00 N 0 OO Common Stock, par value $0.001 per share Kezar Life Sciences, Inc. 4000 Shoreline Court Suite 300 South San Francisco CA 94080 This Schedule 13D/A (this "Statement") amends the Schedule 13D (the "Original Schedule 13D") filed on October 8, 2024 as amended on April 1, 2026. Items 4 and 5 of the Statement are hereby amended and supplemented to the extent hereinafter expressly set forth. Except as amended hereby, the original disclosure set forth in the Statement shall remain unchanged. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Original Schedule 13D. Item 4 of the Original Schedule 13D is hereby amended to add the following: Closing of the Merger: On May 11, 2026, the Issuer completed its merger with Aurinia Pharma U.S., Inc. ("Parent") and Parent's wholly-owned subsidiary, Aurinia Merger Sub, Inc. ("Merger Sub") pursuant to the terms of the Merger Agreement, whereby Merger Sub merged with and into the Issuer, in accordance with the General Corporation Law of the State of Delaware, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, on May 11, 2026, each issued and outstanding share of the Issuer's Common Stock was cancelled. The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons do not own any shares of the Issuer's Common Stock. See item 5(a) above. Except as described in this Amendment No. 2, there have been no transactions in the Issuer's Common Stock during the past 60 days by the Reporting Persons. No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons. The Reporting Persons ceased to be beneficial owners of 5% or more of the Issuer's Common Stock on May 11, 2026. TANG CAPITAL MANAGEMENT, LLC /s/ Kevin Tang Manager 05/13/2026 KEVIN TANG /s/ Kevin Tang Self 05/13/2026 TANG CAPITAL PARTNERS, LP /s/ Kevin Tang Manager, Tang Capital Management, LLC, General Partner 05/13/2026 TANG CAPITAL PARTNERS INTERNATIONAL, LP /s/ Kevin Tang Manager, Tang Capital Management, LLC, General Partner 05/13/2026 TANG CAPITAL PARTNERS III, INC /s/ Kevin Tang Chief Executive Officer 05/13/2026 TANG CAPITAL PARTNERS IV, INC /s/ Kevin Tang Chief Executive Officer 05/13/2026 CONCENTRA BIOSCIENCES, LLC /s/ Kevin Tang Chief Executive Officer 05/13/2026